The corona vaccine from the pharmaceutical company Moderna has an efficiency of 94.1 percent. It shows the full results of Phase 3 studies.
Moderna will on Monday apply for conditional approval of the vaccine in Europe and an emergency approval in the United States.
The studies show that there are no serious concerns about the safety of the vaccine, the company announces.
At the same time, Moderna reports a 100 percent success rate when it comes to preventing serious cases of covid-19.
With the application for emergency approval expected to be sent to the U.S. Drug Administration on Monday, it is likely that Moderna’s vaccine will be the second to be approved in the United States this year.
Pfizer and German Biontech are a week longer in the process than Moderna.
/ ritzau / Reuters
